This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1163 entries already.
In an oversubscribed Series B round led by LSP, Paris-based DNA Script raised US$38.5. Bpifrance and existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners contributed.
Researchers from Universities Nijmegen and Naples have presented a retinal AAV-based gene therapy delivery system that can express huge genetic elements by assembling protein fragments from several vectors.
Molecular diagnostics company Mobidiag has received an EIB loan to accelerate the development and commercialisation of its in vitro diagnostic solutions for infectious diseases.
Privately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured 62m from private investors including the Neri and Dompé families to push registration of two wholly owned Phase III […]
Roche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its […]
Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
The Swiss Biotech Day has long become the standard annual get-together of the Swiss biopharmaceutical industry. And Basel, as one of the most vivid cities in terms of biotechnological and […]
The round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
US scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).
The European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs has again received project funding from the Innovative Medicine’s Initiative.